Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
67.42(c) 67.51(c) 68.65(c) 69.29(c) 68.77(c) Last
7 863 335 5 489 219 8 434 161 8 678 419 6 928 016 Volume
-0.01% +0.13% +1.69% +0.93% -0.75% Change
More quotes
Financials (USD)
Sales 2021 24 680 M - -
Net income 2021 6 885 M - -
Net Debt 2021 21 984 M - -
P/E ratio 2021 13,0x
Yield 2021 4,09%
Sales 2022 23 833 M - -
Net income 2022 7 010 M - -
Net Debt 2022 17 208 M - -
P/E ratio 2022 12,6x
Yield 2022 4,29%
Capitalization 86 250 M 86 250 M -
EV / Sales 2021 4,39x
EV / Sales 2022 4,34x
Nbr of Employees 13 600
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular... 
More about the company
Ratings of Gilead Sciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about GILEAD SCIENCES, INC.
04:43aGILEAD SCIENCES'á : Lymphatic System Cancer Drug Shows 94% Response Rate in Foll..
MT
06/14GILEAD SCIENCES, INC. : Ex-dividend day for
FA
06/12GILEAD SCIENCESá : Longer-term Data for Kite's Yescarta« in Relapsed or Refracto..
BU
06/11STREET COLOR : Gilead Sciences' EMA States Causal Relationship Between Remdesivi..
MT
06/11GILEAD SCIENCESá : EMA Recommends Change To Product Information For Remdesivir T..
RE
06/11GILEAD SCIENCESá : U.S. Food and Drug Administration Approves New Formulation of..
AQ
06/11GILEAD SCIENCESá : Gets FDA Approval to Expand Hepatitis C Drug Indication to In..
MT
06/10GILEAD SCIENCESá : U.S. Food and Drug Administration Approves New Formulation of..
BU
06/09MARKET CHATTER : Samsung Biologics Signs $269 Million Drug Manufacturing Deal wi..
MT
06/08S.Korean stocks end lower, investors look to U.S. inflation data
RE
06/07LUPINá : Gets US FDA Nod to Market HIV Infection Treatment Drug
MT
06/07LUPINá : Gets US FDA's Approval for Generic Version of HIV Drug Truvada
MT
06/07GILEAD SCIENCESá : Trodelvy Demonstrates Superior Outcomes to Standard of Care i..
AQ
06/07GILEAD SCIENCESá : Kite's Tecartus Demonstrates High Response Rate in Adults Wit..
AQ
06/04GILEAD SCIENCESá : Kite's Tecartus« Demonstrates High Response Rate in Adults Wi..
BU
More news
News in other languages on GILEAD SCIENCES, INC.
06/04Galapagos publiceert onderzoeksdata over filgotinib
06/03Covid, accordo Ue per 55.000 dosi trattamento sperimentale Roche-Regeneron
06/02DGAP-NEWS : MorphoSys übernimmt Constellation -2-
06/02DGAP-ADHOC : MorphoSys AG übernimmt Constellation -2-
05/18Galapagos start nieuwe studie naar filgotinib
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 75,15 $
Last Close Price 68,77 $
Spread / Highest target 45,4%
Spread / Average Target 9,27%
Spread / Lowest Target -12,8%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966
BEIGENE, LTD.34.26%31 922